Find Clinical Trial

Home » Find Clinical Trials » Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer’s Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study.

Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer’s Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study.

← Back

Study Phase	Phase 2

Therapeutic Area	Neuropsychiatric Diseases

Indication	Alzheimer's disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S038093

Active Substance Code	S038093

Protocol Code	CL2-38093-012

EudraCT Code	2011-005862-40

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.